632352-56-8

Usage

Uses

Used in Pharmaceutical Synthesis:
1-Boc-3-phenylpiperidin-4-one is used as a key intermediate in the synthesis of pharmaceuticals for its ability to form a variety of bioactive compounds. The presence of the Boc protecting group allows for selective reactions, facilitating the creation of complex molecular structures with potential therapeutic applications.
Used in Research Chemicals:
In the field of research chemicals, 1-Boc-3-phenylpiperidin-4-one serves as a versatile building block for the development of new chemical entities. Its structural features and reactivity make it suitable for exploring novel chemical spaces and discovering compounds with unique biological activities.
Used in Medicinal Chemistry:
1-Boc-3-phenylpiperidin-4-one is utilized as a precursor in medicinal chemistry for the design and synthesis of potential drug candidates. Its nitrogen-containing ring system can be further modified to enhance pharmacokinetic and pharmacodynamic properties, leading to the development of more effective and safer therapeutic agents.
Used in Drug Discovery Research:
In drug discovery research, 1-Boc-3-phenylpiperidin-4-one plays a crucial role as a starting material for the synthesis of diverse chemical libraries. These libraries are screened for biological activity, providing a rich source of leads for the development of new drugs targeting various diseases and conditions.

InChI:InChI=1/C16H21NO3/c1-16(2,3)20-15(19)17-10-9-14(18)13(11-17)12-7-5-4-6-8-12/h4-8,13H,9-11H2,1-3H3

Upstream product

• 108-86-1 bromobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 910875-39-7 4-oxo-3-phenylpiperidine hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1345345-81-4 1-benzyl-3-phenyl-4-piperidone hydrochloride 
• 1384264-55-4 C₂₁H₂₃NO₃ 
• 446302-83-6 1-N-benzyl-3-phenyl-4-piperidone 

Relevant academic research and scientific papers

Oxidation of Nonactivated Anilines to Generate N-Aryl Nitrenoids

A low-temperature, protecting-group-free oxidation of 2-substituted anilines has been developed to generate an electrophilic N-aryl nitrenoid intermediate that can engage in C-NAr bond formation to construct functionalized N-heterocycles. The exposure of 2-substituted anilines to PIFA and trifluoroacetic acid or 10 mol percent Sc(OTf)3 triggers nitrenoid formation, followed by productive and selective C-NAr and C-C bond formation to yield spirocyclic- or bicyclic 3H-indoles or benzazepinones. Our experiments demonstrate the breadth of these oxidative processes, uncover underlying fundamental elements that control selectivity, and demonstrate how the distinct reactivity patterns embedded in N-aryl nitrenoid reactive intermediates can enable access to functionalized 3H-indoles or benzazepinones.

I(III)-catalyzed oxidative cyclization - Migration tandem reactions of unactivated anilines

An I(III)-catalyzed oxidative cyclization-migration tandem reaction using Selectfluor as the oxidant was developed that converts unactivated anilines into 3H-indoles is reported herein. The reaction requires as little as 1 mol % of the iodocatalyst and is mild, tolerating pyridine and thiophene functional groups, and the dependence of the diastereoselectivity of the process on the identity of the iodoarene or iodoalkane precatalyst suggests that the catalyst is present for the stereochemical determining C-N bond forming step.

PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES

Disclosed are compounds of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6,R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

Design, structure-activity relationship, and highly efficient asymmetric synthesis of 3-phenyl-4-benzylaminopiperidine derivatives as novel neurokinin-1 receptor antagonists

We synthesized a series of novel 3-phenyl-4-benzylaminopiperidine derivatives that were identified as potent tachykinin NK1 receptor antagonists by structural modification of the 3-benzhydrylpiperidone derivative through high-throughput screening. N-{2-[(3R,4S)-4-({2-Methoxy-5-[5-(trifluoromethyl)- 1Htetrazol-1-yl]benzyl}amino)-3-phenyl-1-piperidinyl]-2-oxoethyl}acetamide ((+)-39) was found to be one of the most potent tachykinin NK1 receptor antagonists with high metabolic stability. Highly efficient asymmetric synthesis of (+)-39 was achieved via dynamic kinetic resolution.

NK1 and NK3 antagonists

The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.